跳至主要内容
临床试验/NCT01408446
NCT01408446已完成2 期

A Randomized, Double-Blind, Placebo Control Trial Comparing Effects and Safety of DANSHU Capsule(Menthol) and Placebo on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients

Zhiming Zhu1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2012年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
36
试验地点
1
主要终点
The decrease in diastolic blood pressure after an 8-week oral menthol administration

研究概览

简要总结

Prehypertension and mild hypertension are associated with an increased risk of atherosclerosis and coronary artery disease, and often complicated with the metabolic disorder of glucose and lipid. The comprehensive prevention of hypertension is still an important and complex clinical issue. Peppermint is a popular flavoring agent, and peppermint tea help relax tension and could lower blood pressure. The effect of oral peppermint on blood pressure is not consistent, however, our previous animal study has shown that oral administration of menthol, the main component of peppermint, could reduce 24-hour mean arterial systolic and diastolic blood pressure in spontaneous hypertensive rats. Furthermore, menthol increases uncoupling protein(UCP)1 dependent thermogenesis and energy expenditure through transient receptor potential melastatin(TRPM)8 activation, and helps prevent obesity and metabolic disorders. In a prospective, double-blind, randomized, and parallel-group study, we will evaluate the effects of DANSHU capsule(menthol) on blood pressure and metabolic parameters in prehypertensive and mild hypertensive patients. This study will help develop future comprehensive prevention and treatment strategies for hypertension.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Blood pressure: 120mmHg≤SBP<160mmHg, and/or 80mmHg≤DBP<100mmHg

排除标准

  • Hypertension: SBP≥160mmHg, or DBP≥100mmHg
  • known allergy to trial drugs
  • Myocardial infarction or cerebrovascular accident in the year preceding the trial
  • Clinical Congestive Heart Failure
  • Secondary hypertension
  • Pregnancy or lactating women
  • Malignant tumor
  • Gastroesophageal reflux or gastroduodenal ulcer
  • History of hepatitis or cirrhosis
  • History of kidney disease
  • Body weight﹤35Kg

研究组 & 干预措施

Menthol

Active Comparator

Interventions Drug: Menthol Arms: Group 1

干预措施: Menthol (Drug)

Placebo

Placebo Comparator

Interventions Drug: Placebo Arms: Group 2

干预措施: Placebo (Drug)

结局指标

主要结局

The decrease in diastolic blood pressure after an 8-week oral menthol administration

时间窗: 8 weeks

Evaluate the effects of DANSHU capsule(menthol) on blood pressure and metabolic parameters in prehypertensive and mild hypertensive patients after an 8-week oral administration.

次要结局

未报告次要终点

研究者

发起方
Zhiming Zhu
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Zhiming Zhu

Chief Scientist of the National Key Basic Research and Development Program (973 Program)

Third Military Medical University

研究点 (1)

Loading locations...

相似试验

Effects and Safety of Menthol on Blood Pressure and... | 临床试验